Using MRI scans to improve prostate cancer monitoring
A Randomised Controlled Trial of Regular MRI Scans Compared to Standard Care in Patients With Prostate Cancer Managed Using Active Surveillance
This study is testing if regular MRI scans can help men with low to medium risk prostate cancer on active surveillance better monitor their condition compared to the usual PSA tests and exams.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1263 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Imperial College London Academic / other |
| Locations | 12 sites (Ascot, Berkshire and 11 other locations) |
| Trial ID | NCT06280781 on ClinicalTrials.gov |
What this trial studies
This intervention focuses on patients with low to medium risk prostate cancer who are on active surveillance. It aims to compare the effectiveness of regular MRI scans against the current NICE-defined strategy for detecting cancer progression over a five-year period. Patients will be randomly assigned to receive either MRI scans or the standard care, which includes PSA tests and rectal examinations. The study will evaluate whether MRI can detect progression more effectively and at a lower cost to the NHS.
Who should consider this trial
Good fit: Ideal candidates are men aged 18 and older with localized prostate cancer who have chosen active surveillance.
Not a fit: Patients who have been on active surveillance for more than 9 months or have contraindications to MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of prostate cancer progression, potentially improving patient outcomes and reducing unnecessary treatments.
How similar studies have performed: Other studies have shown promise in using MRI for cancer monitoring, but this specific approach is novel in the context of active surveillance for prostate cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or above (no upper limit) * Patients with a prostate (either cis-male gender or trans-female gender with no prior androgen deprivation hormone use at all). * Diagnostic bi-parametric or multiparametric MRI * Diagnostic systematic biopsy +/- targeted biopsy * A histological diagnosis of localised prostate cancer * Patient chosen active surveillance Exclusion Criteria: * On active surveillance for greater than 9 months prior to screening date. * Contraindication to MRI or gadolinium contrast * Previous hip replacement to both hips * Contraindication to performing a biopsy guided by a transrectal ultrasound probe
Where this trial is running
Ascot, Berkshire and 11 other locations
- Heatherwood Hospital — Ascot, Berkshire, United Kingdom (Recruiting)
- Darent Valley Hospital — Dartford, Kent, United Kingdom (Recruiting)
- Bradford Royal Infirmary — Bradford, United Kingdom (Recruiting)
- St Peter's Hospital — Chertsey, United Kingdom (Recruiting)
- Charing Cross Hospital — London, United Kingdom (Recruiting)
- Kings College London — London, United Kingdom (Recruiting)
- West Middlesex Hospital — London, United Kingdom (Recruiting)
- Freeman Hospital — Newcastle upon Tyne, United Kingdom (Recruiting)
- Glan Clywd Hospital — Rhyl, United Kingdom (Recruiting)
- Northern Lincolnshire and Goole NHS Foundation Trust — Scunthorpe, United Kingdom (Recruiting)
- Southampton University Hospital — Southampton, United Kingdom (Recruiting)
- North Cumbria — Whitehaven, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Hashim Ahmed
- Email: hashim.ahmed@imperial.ac.uk
- Phone: +44 (0)20 7594 1660
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.